相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies
Nader S. Abutaleb et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Screening for potent and selective anticlostridial leads among FDA-approved drugs
Ahmed AbdelKhalek et al.
JOURNAL OF ANTIBIOTICS (2020)
Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections
Nader S. Abutaleb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection
Nader S. Abutaleb et al.
SCIENTIFIC REPORTS (2020)
Antibacterial and antivirulence activities of auranofin against Clostridium difficile
Ahmed AbdelKhalek et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Antibiotic-Induced Disruption of Gut Microbiota Alters Local Metabolomes and Immune Responses
Lin Sun et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)
Epidemiologic Trends in Clostridioides difficile Infections in a Regional Community Hospital Network
Nicholas A. Turner et al.
JAMA NETWORK OPEN (2019)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci
Haroon Mohammad et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Repurposing ebselen for decolonization of vancomycin-resistant enterococci (VRE)
Ahmed AbdelKhalek et al.
PLOS ONE (2018)
Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci
Ahmed AbdelKhalek et al.
SCIENTIFIC REPORTS (2018)
In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens
Waleed Younis et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Burden of Clostridium difficile infection: Associated hospitalization in a cohort of middle-aged and older adults
Yingxi Chen et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2017)
Clostridium difficile infection
Wiep Klaas Smits et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
George G. Zhanel et al.
CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY (2015)
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
David Brown
NATURE REVIEWS DRUG DISCOVERY (2015)
Auranofin: Repurposing an Old Drug for a Golden New Age
Christine Roder et al.
DRUGS IN R&D (2015)
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection
Simon D. Baines et al.
ANTIBIOTICS-BASEL (2015)
Fidaxomicin Failures in Recurrent Clostridium difficile Infection: A Problem of Timing
Robert Orenstein
CLINICAL INFECTIOUS DISEASES (2012)
Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain
Laurica A. Petrella et al.
CLINICAL INFECTIOUS DISEASES (2012)
Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management
David W. Eyre et al.
CLINICAL INFECTIOUS DISEASES (2012)
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Oliver A. Comely et al.
CLINICAL INFECTIOUS DISEASES (2012)
Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence
Konstantinos Z. Vardakas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Models for the study of Clostridium difficile infection
Emma L. Best et al.
GUT MICROBES (2012)
Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection
Mark Miller
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea
Kyu Sik Jung et al.
GUT AND LIVER (2010)
Clostridium difficile infection An overview of the disease and its pathogenesis, epidemiology and interventions
V. K. Viswanathan et al.
GUT MICROBES (2010)
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
Wafa N. Al-Nassir et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Historical perspectives on studies of Clostridium difficile and C difficile infection
John G. Bartlett
CLINICAL INFECTIOUS DISEASES (2008)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
Recurrent Clostridium difficile diarrhoea
L Kyne et al.
GUT (2001)
分享论文
